AI Article Synopsis
- Pathologic re-review of TURBT specimens at a tertiary care center was evaluated to understand its impact on disease risk stratification for bladder cancer patients.
- Out of 173 patients whose specimens were re-reviewed, changes in grade, clinical stage, and risk stratification were observed, particularly in those with less advanced (
- The study found that re-review by a GU pathologist affected more than 20% of patients' risk assessments, highlighting its importance in potentially altering patient management strategies.
Article Abstract
Objectives: Pathologic re-review of transurethral resection of bladder tumor (TURBT) specimen is a common practice at our tertiary care center, but its impact on disease risk stratification remains unknown. We sought to determine how pathologic re-review of specimen initially read at an outside institution changed grade, clinical T (cT) stage, and AUA non-muscle-invasive bladder cancer (NMIBC) risk stratification.
Methods And Materials: The laboratory information system was searched for patients who underwent TURBT from 2021 to 2022, yielding 561 records. 173 patients met inclusion criteria: 113 with
Results: For
Conclusions: Re-review of TURBT pathology by a dedicated GU pathologist led to change in AUA NMIBC risk stratification in over one-fifth of patients, with potential for changing management.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.urolonc.2024.05.020 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!